Ankündigung • Aug 08
Terumo Corporation Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2027 Terumo Corporation revised consolidated earnings guidance for the fiscal year ending March 31, 2027. For the year, the company now expects revenue to be JPY 1,239,000 million; operating profit to be JPY 257,500 million; profit attributable to owners of parent to be JPY 193,100 million or basic earnings per share to be JPY 130.91 against previous guidance of revenue of JPY 1,239,000 million; operating profit of JPY 224,500 million; profit attributable to owners of parent of JPY 165,300 million or basic earnings per share of JPY 112.06. Reasons for revisions: The Company has revised upward its full-year consolidated financial guidance for adjusted operating profit, reflecting the refund of U.S. tariffs received in the first quarter of the fiscal year ending March 31, 2027. The Company has also revised upward its full-year consolidated financial guidance for operating profit and profit for the year attributable to owners of the parent, reflecting the refund of U.S. tariffs and the settlement proceeds received in the first quarter of the fiscal year ending March 31, 2027. Ankündigung • Jun 29
Terumo Interventional Systems Completes First Procedure Using Opuswave Dual Sensor Imaging System in the United States Terumo Interventional Systems, a division of Terumo Corporation, recently completed the first procedure using its OPUSWAVE Dual Sensor Imaging System. The procedure, performed on June 15 at Mount Sinai Fuster Heart Hospital in New York, represents a significant milestone in advancing intravascular imaging in the United States. The OPUSWAVE Imaging System features the DualView Imaging Catheter, combining Optical Frequency Domain Imaging (OFDI) and intravascular ultrasound (IVUS) in a single platform to provide simultaneous, complementary views of the coronary anatomy. This first U.S. case represents an important step in bringing next-generation intravascular imaging capability to physicians nationwide, supporting more informed treatment strategies across a broad range of coronary interventions. It also addresses a long-standing clinical challenge: the need to balance the deep vessel visualization of IVUS with the high-resolution surface detail of OFDI. By integrating both modalities into a single catheter, physicians can assess lesion morphology, plaque composition and stent deployment with a more comprehensive perspective – without compromise. The OPUSWAVE Imaging System enables physicians to see the full picture. This 'see more, know more' capability directly reflects what physicians identified as most valuable in recent market research: clearer understanding, better procedural decisions and increased diagnostic confidence when imaging complex coronary disease. The OPUSWAVE Imaging System eliminates that tradeoff by providing both IVUS and OFDI imaging in a single catheter, providing the physician the opportunity to leverage the strengths of each modality simultaneously. This provides the physician with increased clarity and insight for more informed decision–making in real-time, leading to greater confidence when treating the individual patient. The DualView Imaging Catheter is engineered for performance and deliverability, featuring a 2.6 Fr profile, 6 Fr guide compatibility, and advanced hydrophilic coating. It also offers a 150 mm pullback for both IVUS and OFDI, delivering the longest single-run pullback length. With flexible imaging modes – including IVUS-only, OFDI-only, or simultaneous dual imaging – the system allows physicians to tailor imaging to each case while maintaining workflow efficiency. Ankündigung • Jun 23
Terumo Corporation to Report Q1, 2027 Results on Aug 07, 2026 Terumo Corporation announced that they will report Q1, 2027 results on Aug 07, 2026 Ankündigung • May 15
Terumo Corporation, Annual General Meeting, Jun 26, 2026 Terumo Corporation, Annual General Meeting, Jun 26, 2026. Ankündigung • Apr 02
Terumo Corporation to Report Q4, 2026 Results on May 15, 2026 Terumo Corporation announced that they will report Q4, 2026 results on May 15, 2026 Ankündigung • Dec 17
Terumo Corporation to Report Q3, 2026 Results on Feb 13, 2026 Terumo Corporation announced that they will report Q3, 2026 results on Feb 13, 2026 Ankündigung • Oct 30
Terumo Corporation (TSE:4543) completed the acquisition of remaining 99.5% stake in OrganOx Limited from a group of shareholders. Terumo Corporation (TSE:4543) has entered into a definitive agreement to acquire remaining 99.5% stake in OrganOx Limited from a group of shareholders for $1.5 billion on August 23, 2025. Upon completion of the transaction, OrganOx will become a wholly owned subsidiary of Terumo. The transaction will be funded from cash on hand and borrowings.
For the period ending December 31, 2024, OrganOx Limited reported total revenue of $69.14 million and EBIT of $9.01 million. As of December 31, 2024, OrganOx Limited reported total assets of $96.9 million and total common equity of $71.56 million.
The transaction is subject to approval by regulatory board / committee. The transaction is expected to close in FY2025.
Perella Weinberg Partners and Piper Sandler served as OrganOx’s financial advisors and Robbie McLaren, Ross McAloon, Charles Ruck, Elizabeth Richards, Betty Pang, Chad Jennings, Sean Finn, Maj Vaseghi, Kendall Burnett, Hector Armengod, Patrick English, Catherine Hein and Philipp Studt of Latham & Watkins acted as legal counsel to OrganOx in this transaction.
Terumo Corporation (TSE:4543) completed the acquisition of remaining 99.5% stake in OrganOx Limited from a group of shareholders on October 29, 2025. Ankündigung • Oct 24
Terumo Interventional Systems Announces its New OPUSWAVE Dual Sensor Imaging System and DualView®? Imaging Catheter Receive FDA 510(k) Clearance Terumo Interventional Systems (TIS) has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its OPUSWAVE®? Dual Sensor Imaging System. The OPUSWAVE Imaging System features the DualView®? imaging catheter, which also received FDA 510(k) clearance. The OPUSWAVE imaging System combines Optical Frequency Domain Imaging (OFDI) and intravascular ultrasound (IVUS) to enable simultaneous views, offering physicians the ability to comprehensively evaluate coronary artery disease (CAD). While this marks Terumo's imaging debut in the US market, the company is already a recognized leader in the single modality imaging space in Japan, where adoption of imaging in percutaneous coronary intervention (PCI) procedures is the highest in the world. What makes the OPUSWAVE Imaging System unique is the DualView imaging catheter, which offers a 150mm maximum pullback length. It also has a 2.6 Fr. imaging profile, 6 Fr. guide compatibility, advanced hydrophilic coating, and a variable pullback speed of up to 40mm/second in dual mode. Ankündigung • Sep 19
Terumo Corporation to Report Q2, 2026 Results on Nov 12, 2025 Terumo Corporation announced that they will report Q2, 2026 results on Nov 12, 2025 Ankündigung • Aug 25
Terumo Corporation (TSE:4543) has entered into a definitive agreement to acquire 99.5% stake in OrganOx Limited from a group of shareholders in a transaction valued at $1.5 billion. Terumo Corporation (TSE:4543) has entered into a definitive agreement to acquire 99.5% stake in OrganOx Limited from a group of shareholders in a transaction valued at $1.5 billion on August 23, 2025. Upon completion of the transaction, OrganOx will become a wholly owned subsidiary of Terumo.
For the period ending December 31, 2024, OrganOx Limited reported total revenue of $69.14 million and EBIT of $9.01 million. As of December 31, 2024, OrganOx Limited reported total assets of $96.9 million and total common equity of $71.56 million.
The transaction is subject to approval by regulatory board / committee.
Perella Weinberg Partners and Piper Sandler served as OrganOx’s financial advisors and Latham & Watkins acted as legal counsel to OrganOx in this transaction. Ankündigung • Jun 24
Terumo Corporation to Report Q1, 2026 Results on Aug 07, 2025 Terumo Corporation announced that they will report Q1, 2026 results on Aug 07, 2025 Ankündigung • Jun 03
Terumo Neuro Announces EMEA Commercial Availability of the SOFIA™? Flow 88 Neurovascular Aspiration Catheter Terumo Neuro announced the commercial availability of the SOFIA Flow 88 Neurovascular Aspiration Catheter, expanding the company's stroke portfolio with a new large-bore catheter engineered for reliability, procedural flexibility, and physician control. The launch builds on the proven clinical performance and global legacy of the SOFIA™? Catheter line, which has supported more than 500,000 procedures across 170 countries over the past decade. Terumo Neuro is showcasing its complete line of stroke solutions at LINNC Paris this week at Le Carrousel du Louvre, booth number 8. Leveraging more than ten years of neurovascular catheter innovation, physician partnerships and proven clinical performance1-9, the SOFIA™? 88 Neurovascular As inspiration Catheter offers an 0.088-inch inner diameter with proprietary engineering enhancements designed to provide the following benefits: Reach with Confidence - Reliable trackability through challenging anatomy via optimized transition zones and a soft, atraumatic distal tip. Support to Go the Distance - Proximal stability for procedural ease with both short and long sheaths. Atraumatic by Design - Flexibility and reinforcement throughout the entire working length to minimize vessel trauma and support smooth navigation. Engage the Clot with Confidence - Highly compliant proprietary SOFIA tip beyond the marker band expands conforming to the clot. Aspirate with Confidence - Next generation SOFIA technology with nitinol braid and coil reinforcement maintains lumen integrity. The SOFIA™ 88 Neurovascular Aspiration Catheter is compatible with the SOFIA™ Plus 6F Aspiration Catheter and supports integration into existing aspiration strategies. Clinical evidence from the SOFAST registry & the SESAME trial—evaluating the SOFIA™ Plus 6F as a first-line approach—demonstrated strong results across speed, efficacy, and safety and overall clinical outcomes. The new SOFIA™ 88 Catheter also seamlessly complements the company's broader stroke solution portfolio, offering a fully integrated approach across aspiration, access, retrieval, and navigation: SOFIA™ and SOFIA™ Plus Aspiration Catheters – Renowned for trackability and clinical performance, ERIC™ Retrieval Device – Designed for thrombus control, procedural efficiency, and versatility, BOBBY™ Balloon Guide Catheter – Reliable flow arrest with streamlined preparation, optimized compatibility and next-generation balloon technology, WEDGE™ Microcatheter – A navigation aid that minimizes ledge effect, HEADWAY™ Microcatheters – Low-profile outer diameter, providing versatility, reliability, and fast access, and TRAXCESS™ Guidewires – Soft-tip design for challenging anatomies. Ankündigung • May 28
Terumo Interventional Systems, Division of Terumo Corporation, Announces Commercial Availability of its ROADSAVER Carotid Stent System Terumo Interventional Systems (TIS), a division of Terumo Corporation, announced the early commercial availability of its FDA-approved ROADSAVER Carotid Stent System. Indicated for use with the Nanoparasol®? Embolic Protection System, ROADSAVER Stent System addresses carotid artery stenosis in patients with increased risk of adverse events following carotid endarterectomy. ROADSAver Stent System is the only carotid artery stenting (CAS) device with an innovative, dual-layer micromesh. It is designed as a closed-cell stent with the flexibility of an open-cell stent, providing increased flexibility and wall apposition in complex anatomies. It is also the first dual-layer micromesh carotid stent approved in the United States, and the only carotid stent system designed to contain plaque to the vessel wall and prevent plaque protrusion, protecting against distal embolization. Available in sizes from 5 to 10 mm in width and 22 to 47 mm in length, ROADSAVER StENT System has a rapid-exchange shaft length of 143 cm. It is also fully re-sheathable and repositionable - even after 50% of the stent's length is deployed. Another important feature is the product's low-profile 5Fr design, which enhances its crossability. Limited market release of the ROADSAVER CarotID Stent System is planned for summer 2025, with full market release anticipated in fall 2025. Ankündigung • May 14
Terumo Corporation, Annual General Meeting, Jun 24, 2025 Terumo Corporation, Annual General Meeting, Jun 24, 2025. Ankündigung • Apr 17
Terumo Blood and Cell Technologies Names Patrick Daly as Chief Business Officer Terumo Blood and Cell Technologies (Terumo BCT) announced the addition of Patrick Daly as its Chief Business Officer as the company continues to expand its capabilities to meet evolving market segments. Daly joins Terumo BCT with over 30 years of business and healthcare industry experience, both domestically and internationally. Most recently, he built the MedTech Global Data franchise at IQVIA, a provider of technology solutions to the life sciences industry. Daly has spent his career building commercial capabilities to deliver organic and inorganic growth. Before joining IQVIA, he was President and CEO of Cohera Medical, and he remains an independent Board Director for BioStem Technologies. He has held successive senior leadership roles in strategic marketing, sales and business development across various regions and businesses of Johnson &Johnson. He earned his Bachelor of Science in Foreign Area Studies from the U.S. Military Academy at West Point. Ankündigung • Mar 20
Terumo Corporation to Report Fiscal Year 2025 Results on May 14, 2025 Terumo Corporation announced that they will report fiscal year 2025 results on May 14, 2025 Ankündigung • Dec 12
Terumo Corporation to Report Q3, 2025 Results on Feb 13, 2025 Terumo Corporation announced that they will report Q3, 2025 results on Feb 13, 2025 Ankündigung • Dec 03
Terumo Interventional Systems Announces Launch of Its R2p Navicross Peripheral Support Catheter Terumo Interventional Systems (TIS), a division of Terumo Corporation announced the launch and commercial availability of its R2P™ NaviCross® peripheral support catheter in the U.S., further expanding the company's radial-to-peripheral (R2P) portfolio. The R2P NaviCross catheter, now available in a 200 cm length, is designed for optimized performance in R2P procedures. Its double-braided, stainless-steel construction is engineered for superior trackability and torque control for lesion crossing in more complex procedures. The new 200 cm R2P NaviCross catheter rounds out the existing R2P portfolio, including the R2P Destination Slender™ guiding sheath, R2P SlenGuide™ guiding catheter, R2P Misago® self-expanding peripheral stent, and R2P Metacross™ RX and R2P Crosstella™ RX dilatation catheters – giving physicians the confidence to complete almost any PAD procedure from the wrist. Ankündigung • Sep 25
Terumo Corporation to Report Q2, 2025 Results on Nov 07, 2024 Terumo Corporation announced that they will report Q2, 2025 results on Nov 07, 2024 Ankündigung • Aug 30
Terumo Corporation (TSE:4543) announces an Equity Buyback for 15,000,000 shares, representing 1.01% for ¥30,000 million. Terumo Corporation (TSE:4543) announces a share repurchase program. Under the program, the company will repurchase up to 15,000,000 shares, representing 1.01% of its issued share capital, for ¥30,000 million. The purpose of the program is to increase shareholder returns, improve capital efficiency, and mitigate the impact on stock supply and demand associated with the offering of our common stock. The repurchased shares will be cancelled. The program will run until December 30, 2024. As of June 30, 2024, the company had 1,484,855,220 shares in issue (excluding treasury stock) and 5,842,060 shares in treasury. Ankündigung • Jun 03
Terumo Corporation to Report Q1, 2025 Results on Aug 08, 2024 Terumo Corporation announced that they will report Q1, 2025 results on Aug 08, 2024 Ankündigung • May 29
Terumo Cardiovascular Announces 510(K) Clearance for the CDI Oneview™? Monitoring System Terumo Cardiovascular announced that the U.S. Food and Drug Administration has granted 510(k) clearance for the CDI OneView Monitoring System. The next-generation CDI Systems platform provides visibility of key patient parameters during cardiopulmonary bypass surgery, critical to perfusion safety and improving patient outcomes. The new CDI OneView System measures or displays up to 22 key parameters, the newest of which are measured flow (Q), cardiac index (CI), regional cerebral oxygen saturation (rSO2), oxygen extraction ratio (O2ER), Area Under the DO2 Curve (AUC), and measured arterial oxygen saturation (SaO2). This innovative system offers maximum configurability and flexibility in how the parameters can be viewed and prioritized to best suit clinical needs and preferences, while continuing to provide the critical information on which clinicians have come to rely. New features and functions of Terumo's latest patient parameter monitoring system were influenced by extensive perfusionist input from leading global cardiovascular institutions. In response to the growing needs of healthcare providers, the new CDI OneView System now provides real-time O2ER, CI, VO2 and DO2 information to help perfusionists maintain a safe threshold for those parameters. Independently published and reviewed clinical research indicates that maintaining optimal levels during cardiopulmonary bypass can help to reduce the incidence of acute kidney injury. Ankündigung • Mar 17
Terumo Corporation to Report Fiscal Year 2024 Results on May 14, 2024 Terumo Corporation announced that they will report fiscal year 2024 results on May 14, 2024 Ankündigung • Feb 09
Terumo Corporation Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024 Terumo Corporation revised consolidated earnings guidance for the fiscal year ending March 31, 2024. For the year, the company expects revenue to be JPY 906,000 million. Operating profit to be JPY 140,000 million. Profit attributable to owners of parent to be JPY 105,000 million. Earnings per share to be JPY 141.18. Ankündigung • Feb 07
Terumo Corporation Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024 Terumo Corporation provided dividend guidance for the fiscal year ending March 31, 2024. For the year, the company expects dividend of JPY 22.00 per share against JPY 21.00 per share paid for the same period a year ago. Ankündigung • Dec 03
Terumo Corporation to Report Q3, 2024 Results on Feb 07, 2024 Terumo Corporation announced that they will report Q3, 2024 results on Feb 07, 2024 Ankündigung • Oct 01
Terumo Corporation to Report Q2, 2024 Results on Nov 14, 2023 Terumo Corporation announced that they will report Q2, 2024 results on Nov 14, 2023 Ankündigung • Aug 10
Terumo Corporation (TSE:4543) announces an Equity Buyback for 5,000,000 shares, representing 0.67% for ¥20,000 million. Terumo Corporation (TSE:4543) announces a share repurchase program. Under the program, the company will repurchase up to 5,000,000 shares, representing 0.67% of its issued share capital, for ¥20,000 million. The purpose of the program is to expand shareholder returns and improve capital efficiency. The repurchased shares will be cancelled. The program will run until March 8, 2024. As of June 30, 2023, the company had 744,644,147 shares in issue (excluding treasury stock) and 3,038,393 shares in treasury. Ankündigung • Jun 21
Terumo Corporation to Report Q1, 2024 Results on Aug 09, 2023 Terumo Corporation announced that they will report Q1, 2024 results on Aug 09, 2023 Ankündigung • May 16
Terumo Corporation, Annual General Meeting, Jun 27, 2023 Terumo Corporation, Annual General Meeting, Jun 27, 2023. Ankündigung • Feb 09
Terumo Corporation Revises Dividend Guidance for Fiscal Year Ending March 31, 2023 Terumo Corporation decided at the Board of Directors meeting held on February 9, 2023 to increase the year-end dividend forecast for fiscal year ending March 31, 2023. The details are as follows. The company revised dividend forecast to JPY 21.00 per share compared to the previous guidance of JPY 19.00 per share paid for the same period a year ago. Reason of the Revision: As a measure to secure high profit margins and sustainable growth, Terumo iscommitted to adequately and actively reinvesting its profits to enhance its corporate value continuously. As for the distribution of profits to shareholders, Terumo has been aiming to steadily increase its dividend payouts to shareholders with the target dividend payout ratio of 30% in the mid to long-term. Ankündigung • Nov 10
Terumo Corporation to Report Q3, 2023 Results on Nov 10, 2023 Terumo Corporation announced that they will report Q3, 2023 results on Nov 10, 2023 Ankündigung • Aug 25
Terumo Corporation (TSE:4543) acquired ReThink Medical, Inc. Terumo Corporation (TSE:4543) acquired ReThink Medical, Inc. on August 11, 2020. Hiroki Kobayashi of Latham & Watkins LLP acted as the legal advisor to Terumo.
Terumo Corporation (TSE:4543) completed the acquisition of ReThink Medical, Inc. on August 11, 2020. Ankündigung • Jul 30
Terumo Corporation (TSE:4543) acquired remaining 80.1% stake in Quirem Medical B.V. for $45 million. Terumo Corporation (TSE:4543) acquired remaining 80.1% stake in Quirem Medical B.V. for $45 million on July 15, 2020. Terumo will make a one-time, up-front payment of USD 20 million with up to USD 25 million additional payments based on the achievement of future milestones by 2030. It will be funded through cash on hand and will not significantly impact the company's financial projections for the current fiscal year ending March 31, 2021.
Terumo Corporation (TSE:4543) completed the acquisition of remaining 80.1% stake in Quirem Medical B.V. on July 15, 2020. Ankündigung • Jun 29
Terumo Corporation to Report Q1, 2021 Results on Aug 06, 2020 Terumo Corporation announced that they will report Q1, 2021 results on Aug 06, 2020 
